抗CD20治疗与抗nephrin抗体在伴微小病变的IgA肾病中的研究
该回顾性队列研究评估了抗CD20单抗联合短程低剂量激素与足量长程激素在伴微小病变的IgA肾病(MCD-IgAN)成人患者中的疗效,并检测了抗nephrin抗体。结果显示两组总缓解率相当,但抗CD20组无复发生存期更长、不良事件和再住院更少;抗nephrin抗体阳性且>150 ng/ml与更高复发风险相关。
要点
- 抗CD20单抗联合短程低剂量激素治疗MCD-IgAN的完全缓解率与足量长程激素相当。
- 抗CD20组完全缓解后无复发生存期更长(中位30.4 vs 17.1个月,P=0.01)。
- 抗nephrin抗体>150 ng/ml与复发风险升高相关(HR=3.93,95%CI 1.18-13.13)。
核心结论
- 抗CD20单抗是成人MCD-IgAN有效且安全的治疗选择。
- 循环抗nephrin抗体可检测到,且与更高复发率相关,可能作为疾病活动度和治疗靶点的生物标志物。
研究设计与样本
- 回顾性队列研究,纳入45例成人MCD-IgAN患者比较抗CD20单抗组与激素组疗效,并在61例MCD-IgAN患者中评估抗nephrin抗体。
主要发现
- 抗CD20单抗组与激素组肾病综合征总缓解率相当。
- 抗CD20单抗组完全缓解后无复发生存期长于激素组(中位30.4 vs 17.1个月,P=0.01)。
- 抗CD20单抗组总不良事件和再住院率显著低于激素组。
- 31.1%(19/61)的MCD-IgAN患者检测到循环抗nephrin抗体,与MCD患者相当。
- 抗nephrin抗体>150 ng/ml者复发风险更高(HR=3.93,95%CI 1.18-13.13),每人年复发率更高(IRR=3.16,95%CI 1.42-7.03),无复发生存期更短(中位14.0 vs 48.3个月,P=0.02)。
关键数值与推荐
- 抗nephrin抗体>150 ng/ml与复发风险升高相关(HR=3.93,95%CI 1.18-13.13)。
- 抗nephrin抗体>150 ng/ml者每人年复发率比值比IRR=3.16(95%CI 1.42-7.03)。
- 抗nephrin抗体>150 ng/ml者无复发生存期中位14.0个月,低于低抗体者的48.3个月(P=0.02)。
- 抗CD20单抗组完全缓解后无复发生存期中位30.4个月,激素组17.1个月(P=0.01)。
临床怎么用
- 对成人MCD-IgAN可考虑抗CD20单抗联合短程低剂量激素方案,以减少激素暴露和不良事件。
- 监测循环抗nephrin抗体水平可能有助于评估疾病活动度和复发风险。
- 抗nephrin抗体>150 ng/ml提示复发风险较高,需加强随访。
局限性
- 回顾性队列设计可能存在选择偏倚和混杂因素。
- 样本量有限(45例比较疗效,61例检测抗体)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In IgA nephropathy (IgAN) with minimal change disease (MCD) (MCD-IgAN), the efficacy of anti-CD20 monoclonal antibodies (mAbs) and the profile of antinephrin antibodies remain poorly understood. METHODS: We evaluated the efficacy of anti-CD20 mAbs or combined short-course low-dose steroids (anti-CD20 mAbs group) compared with full-dose prolonged steroids (steroids group) and assessed the prevalence of antinephrin antibodies in a retrospective cohort of patients with MCD-IgAN. RESULTS: Total remission rates of nephrotic syndrome were comparable between the anti-CD20 mAbs group and the steroids group in 45 adult patients with MCD-IgAN. Notably, the anti-CD20 mAbs group achieved a longer recurrence-free period after complete remission than the steroids group (median 30.4 vs. 17.1 months, P = 0.01). In addition, patients in the anti-CD20 mAbs group experienced significantly fewer total adverse events and rehospitalization rates. Circulating antinephrin antibodies was detected in 31.1% (19/61) of patients with MCD-IgAN, comparable to patients with MCD. Furthermore, patients with antinephrin antibodies > 150 ng/ml exhibited significantly increased hazard risk of recurrence (hazard ratio = 3.93, 95% confidence interval [CI]: 1.18-13.13), higher recurrence rate per person-year (incidence rate ratio: 3.16, 95% CI: 1.42-7.03) and shorter relapse-free interval than those with lower antinephrin antibodies (median 14.0 vs. 48.3 months, P = 0.02). Importantly, antinephrin antibody levels in sequential plasma samples closely tracked clinical course of disease remission and relapses during follow-up. CONCLUSION: Our findings indicate that anti-CD20 mAbs represent an effective and safe therapeutic option for adult patients with MCD-IgAN. Circulating antinephrin antibodies were detectable and associated with a higher relapse rate, suggesting its potential utility as a biomarker of both disease activity and therapeutic target in this disease.
引用
- Liang Y, Yang Z, Yuan X, et al. Anti-CD20 Therapies and Antinephrin Autoantibodies in IgA Nephropathy With Minimal Change Disease. Kidney Int Rep. 2026. PMID: 42440460. doi:10.1016/j.ekir.2026.106622
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。